Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 394

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

A Randomized, Double‐Blind Trial of Abatacept (CTLA‐4Ig) for the Treatment of Giant Cell Arteritis

Open access
Langford, Carol A., Cuthbertson, David, Ytterberg, Steven R., Khalidi, Nader, Monach, Paul A., Carette, Simon, Seo, Philip, Moreland, Larry W., Weisman, Michael, Koening, Curry L., Sreih, Antoine G., Spiera, Robert, McAlear, Carol A., Warrington, Kenneth J., Pagnoux, Christian, McKinnon, Kathleen, Forbess, Lindsy J., Hoffman, Gary S., Borchin, Renée, Krischer, Jeffrey P., Merkel, Peter A., for the Vasculitis Clinical Research Consortium·2017·Arthritis & Rheumatology

Abstract

Objective: To compare the efficacy of abatacept to that of placebo for the treatment of giant cell arteritis (GCA). Methods: In this multicenter trial, patients with newly diagnosed or relapsing GCA were treated with abatacept 10 mg/kg intravenously on days 1, 15, and 29 and week 8, together with prednisone administered daily. At week 12, patients in remission underwent a double‐blinded randomization to continue to receive abatacept monthly or switch to placebo. Patients in both study arms received a standardized prednisone taper, with discontinuation of prednisone at week 28. All patients remained on their randomized assignment until meeting criteria for early termination or until 12 months after enrollment of the last patient. The primary end point was duration of remission (relapse‐free survival rate). Results: Forty‐nine eligible patients with GCA were enrolled and treated with prednisone and abatacept; of these, 41 reached the week 12 randomization and underwent a blinded randomization to receive abatacept or placebo. Prednisone was tapered using a standardized schedule, reaching a daily dosage of 20 mg at week 12 with discontinuation in all patients at week 28. The relapse‐free survival rate at 12 months was 48% for those receiving abatacept and 31% for those receiving placebo (P = 0.049). A longer median duration of remission was seen in those receiving abatacept compared to those receiving placebo (median duration 9.9 months versus 3.9 months; P = 0.023). There was no difference in the frequency or severity of adverse events, including infection, between the treatment arms. Conclusion: In patients with GCA, the addition of abatacept to a treatment regimen with prednisone reduced the risk of relapse and was not associated with a higher rate of toxicity compared to prednisone alone.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.40044

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 394

Metadata

Authors
Langford, C. A., Cuthbertson, D., Ytterberg, S. R., Khalidi, N., Monach, P. A., Carette, S., Seo, P., Moreland, L. W., Weisman, M., Koening, C. L., Sreih, A. G., Spiera, R., McAlear, C. A., Warrington, K. J., Pagnoux, C., McKinnon, K., Forbess, L. J., Hoffman, G. S., Borchin, R., Krischer, J. P., Merkel, P. A., & for the Vasculitis Clinical Research Consortium
Venue
Arthritis & Rheumatology
Publisher
Wiley
Published
2017-03-03
Volume
69
Issue
4
Pages
837-845
ISSN
  • 2326-5191 (ISSN-L)
  • 2326-5205
OpenAlex
W2581891606
Cited by
394
References
38
FWCI
35.64
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.